Search

Your search keyword '"Boutayeb, Wiam"' showing total 27 results
Start Over Author "Boutayeb, Wiam"

Refine your results

27 results on '"Boutayeb, Wiam"'

1. The Dynamics of a Population of Healthy Adults, Overweight/Obese and Diabetics With and Without Complications in Morocco

Author

Mohamed Lamlili, E. N., Boutayeb, Wiam, Boutayeb, Abdesslam, Angrisani, Leopoldo, Series Editor, Arteaga, Marco, Series Editor, Panigrahi, Bijaya Ketan, Series Editor, Chakraborty, Samarjit, Series Editor, Chen, Jiming, Series Editor, Chen, Shanben, Series Editor, Chen, Tan Kay, Series Editor, Dillmann, Rüdiger, Series Editor, Duan, Haibin, Series Editor, Ferrari, Gianluigi, Series Editor, Ferre, Manuel, Series Editor, Hirche, Sandra, Series Editor, Jabbari, Faryar, Series Editor, Jia, Limin, Series Editor, Kacprzyk, Janusz, Series Editor, Khamis, Alaa, Series Editor, Kroeger, Torsten, Series Editor, Li, Yong, Series Editor, Liang, Qilian, Series Editor, Martín, Ferran, Series Editor, Ming, Tan Cher, Series Editor, Minker, Wolfgang, Series Editor, Misra, Pradeep, Series Editor, Möller, Sebastian, Series Editor, Mukhopadhyay, Subhas, Series Editor, Ning, Cun-Zheng, Series Editor, Nishida, Toyoaki, Series Editor, Oneto, Luca, Series Editor, Pascucci, Federica, Series Editor, Qin, Yong, Series Editor, Seng, Gan Woon, Series Editor, Speidel, Joachim, Series Editor, Veiga, Germano, Series Editor, Wu, Haitao, Series Editor, Zamboni, Walter, Series Editor, Zhang, Junjie James, Series Editor, Bekkay, Hajji, editor, Mellit, Adel, editor, Gagliano, Antonio, editor, Rabhi, Abdelhamid, editor, and Amine Koulali, Mohammed, editor

Published
2023
Full Text
View/download PDF

6. The Impact of Obesity on Predisposed People to Type 2 Diabetes: Mathematical Model

Author

Boutayeb, Wiam, Lamlili, Mohamed E. N., Boutayeb, Abdesslam, Derouich, Mohammed, Hutchison, David, Series editor, Kanade, Takeo, Series editor, Kittler, Josef, Series editor, Kleinberg, Jon M., Series editor, Kobsa, Alfred, Series editor, Mattern, Friedemann, Series editor, Mitchell, John C., Series editor, Naor, Moni, Series editor, Nierstrasz, Oscar, Series editor, Pandu Rangan, C., Series editor, Steffen, Bernhard, Series editor, Terzopoulos, Demetri, Series editor, Tygar, Doug, Series editor, Weikum, Gerhard, Series editor, Istrail, Sorin, Series editor, Pevzner, Pavel, Series editor, Waterman, Michael S., Series editor, Ortuño, Francisco, editor, and Rojas, Ignacio, editor

Published
2015
Full Text
View/download PDF

7. A Simulation Model for the Dynamics of a Population of Diabetics with and without Complications Using Optimal Control

Author

Boutayeb, Wiam, Lamlili, Mohamed E. N., Boutayeb, Abdesslam, Derouich, Mohammed, Hutchison, David, Series editor, Kanade, Takeo, Series editor, Kittler, Josef, Series editor, Kleinberg, Jon M., Series editor, Kobsa, Alfred, Series editor, Mattern, Friedemann, Series editor, Mitchell, John C., Series editor, Naor, Moni, Series editor, Nierstrasz, Oscar, Series editor, Pandu Rangan, C., Series editor, Steffen, Bernhard, Series editor, Terzopoulos, Demetri, Series editor, Tygar, Doug, Series editor, Weikum, Gerhard, Series editor, Istrail, Sorin, Series editor, Pevzner, Pavel, Series editor, Waterman, Michael S., Series editor, Ortuño, Francisco, editor, and Rojas, Ignacio, editor

Published
2015
Full Text
View/download PDF

13. A mathematical model on the effect of growth hormone on glucose homeostasis

Author

Hannah Al Ali, Merabet Nora, Boutayeb Wiam, Boutayeb Abdesslam, School of Mathematics, Statistics & Computing, Emirates Aviation University, Dubai, UAE, Department of Mathematics, and Université Mohamed 1 Oujda MAROC

Subjects
Recepteurs d'insuline, Equilibrium, medicine.medical_treatment, [MATH.MATH-DS]Mathematics [math]/Dynamical Systems [math.DS], 030209 endocrinology & metabolism, Growth hormone, Stabilité, 03 medical and health sciences, Receptor Dynamics, Insuline, 0302 clinical medicine, Recpteurs d'insuline, medicine, Glucose homeostasis, Insulin, MOTS-CLÉS : Modèle, [MATH]Mathematics [math], Receptor, Hormone de Croissance, 030304 developmental biology, Cellules beta, 0303 health sciences, β-Cell Mass, Free Fatty Acids, Chemistry, Hormone de croissance KEYWORDS : Model, General Medicine, Glucose, Acides gras libres, Growth Hormone, Biophysics, Equilibre, Stability, Cellules β, Simulation, Model
Abstract

Extending an existing model devoted to the interaction between β-Cell Mass, Insulin, Glucose, Receptor Dynamics and Free Fatty Acids in glucose regulatory system simulation, this paper proposes a mathematical model introducing the effect of growth hormone on the glucose homeostasis alongside the other variables. Stability analysis is carried out and pragmatic explanation of the equilibrium points is emphasized. Finally, simulation illustrated how β-Cell Mass, Insulin, Glucose, Receptor Dynamics, Free Fatty Acids and Growth Hormone may vary with different values of some parameters in the model., Prolongeant un précédent model publié dédié à l'interaction entre les cellules beta, l'insuline, le glucose, les recpteurs d'insuline et les acides gras libres, cet article propose un modele mathématique introduisant l'effet de l'hrmone de croissance sur la homéostasie du glucose. L'analyse de stabilité a été suivie d'explication pratique des points d'équilibre. Enfin, la simulation a illustré comment les cellules beta, l'insuline, le glucose, les recpteurs d'insuline, les acides gras libres et l'hormone de croissance peuvent varier en fonction des différentes valeurs de certains paramètres.

Published
2019

15. Estimation of the cost of treatment by chemotherapy for early breast cancer in Morocco

Author

Boutayeb Saber, Boutayeb Abdesslam, Ahbeddou Naoual, Boutayeb Wiam, Ismail Essaadi, Tazi Mehdi, and Errihani Hassan

Subjects
Medicine (General), R5-920
Abstract

Abstract Background Breast cancer is the first cancer in women both in incidence and mortality. The treatment of breast cancer benefited from the progress of chemotherapy and targeted therapies, but there was a parallel increase in treatment costs. Despite a relatively high incidence of many sites of cancer, so far, there is no national register for this disease in Morocco. The main goal of this paper is to estimate the total cost of chemotherapy in the early stages of breast cancer due to its frequency and the chances of patients being cured. This study provides health decision-makers with a first estimate of costs and the opportunity to achieve the optimal use of available data to estimate the needs of antimitotics and trastuzumab in Morocco. Method We start by evaluating the individual cost according to the therapeutic sub-groups, namely: 1. Patients needing chemotherapy with only anthracycline-based therapy. 2. Patients needing chemotherapy with both anthracycline and taxane but without trastuzumab. 3. Patients needing trastuzumab in addition to chemotherapy. For each sub-group, the protocol of treatment is described, and the individual costs per unit, and for the whole cycle, are evaluated. Then we estimate the number of women suffering from breast cancer on the basis of two data bases available in Morocco. Finally, we calculate the total annual cost of treatment of breast cancer in Morocco. Results The total cost of breast cancer in Morocco is given in Moroccan dirhams (MAD), the US dollar at the current exchange rate (MAD 10 = USD 1.30) and in international dollars or purchasing power parity (MAD 10 = PPP 1.95). The cost of a therapy with trastuzumab is 8.4 times the cost of a sequential chemotherapy combining anthracycline and taxane, and nearly 60 times the cost of chemotherapy based on anthracycline alone. Globally, between USD 13.3 million and USD 28.6 million need to be devoted every year by the Moroccan health authorities to treat women with localized breast cancer in keeping with international recommendations. Discussion According to our estimation methods, the complete cost of adjuvant chemotherapy including trastuzumab will range from 1.3 to 2.4% of the global budget of the Moroccan Health Department (MAD 9.8 billion or USD 1.274 billion). Unfortunately, only one-third of the Moroccan population has healthcare insurance whereas for each patient the treatment with chemotherapy alone costs 1.15 times the annual minimum income (MAD 23,710 or USD 3,082), and treatment requiring both chemotherapy and trastuzumab costs 9.76 times the annual minimum income. For the tumour over expressing HER2Neu, we need to treat 25 women in order to save (cure) one woman: the calculated cost for one life saved is USD 663,000. The question is, is it cost-effective for an emerging country? Conclusion In this paper we aimed at evaluating the total cost of chemotherapy in the early stages of breast cancer in order to provide health decision-makers with a first estimation and a good opportunity for the optimal use of available data for the needs of antimitotics and trastuzumab in Morocco. Different protocols were considered and the individual cost of the whole treatment was given according to therapies using anthracycline alone, sequential chemotherapy combining anthracycline and taxane, and sequential chemotherapy with trastuzumab. According to our estimations, Moroccan health authorities need to devote between USD 13.3 million and USD 28.6 million every year in order to treat women suffering from localized breast cancer in ways consistent with international recommended standards.

Published
2010
Full Text
View/download PDF

25. Estimation of the cost of treatment bychemotherapy for early breast cancer in Morocco.

Author

Boutayeb, Saber, Boutayeb, Abdesslam, Ahbeddou, Naoual, Boutayeb, Wiam, Ismail, Essaadi, Tazi, Mehdi, and Errihani, Hassan

Subjects
DRUG therapy, BREAST cancer treatment, CANCER in women, MEDICAL care costs
Abstract

Background: Breast cancer is the first cancer in women both in incidence and mortality. The treatment of breast cancer benefited from the progress of chemotherapy and targeted therapies, but there was a parallel increase in treatment costs. Despite a relatively high incidence of many sites of cancer, so far, there is no national register for this disease in Morocco. The main goal of this paper is to estimate the total cost of chemotherapy in the early stages of breast cancer due to its frequency and the chances of patients being cured. This study provides health decision-makers with a first estimate of costs and the opportunity to achieve the optimal use of available data to estimate the needs of antimitotics and trastuzumab in Morocco. Method: We start by evaluating the individual cost according to the therapeutic sub-groups, namely: 1. Patients needing chemotherapy with only anthracycline-based therapy. 2. Patients needing chemotherapy with both anthracycline and taxane but without trastuzumab. 3. Patients needing trastuzumab in addition to chemotherapy. For each sub-group, the protocol of treatment is described, and the individual costs per unit, and for the whole cycle, are evaluated. Then we estimate the number of women suffering from breast cancer on the basis of two data bases available in Morocco. Finally, we calculate the total annual cost of treatment of breast cancer in Morocco. Results: The total cost of breast cancer in Morocco is given in Moroccan dirhams (MAD), the US dollar at the current exchange rate (MAD 10 = USD 1.30) and in international dollars or purchasing power parity (MAD 10 = PPP 1.95). The cost of a therapy with trastuzumab is 8.4 times the cost of a sequential chemotherapy combining anthracycline and taxane, and nearly 60 times the cost of chemotherapy based on anthracycline alone. Globally, between USD 13.3 million and USD 28.6 million need to be devoted every year by the Moroccan health authorities to treat women with localized breast cancer in keeping with international recommendations. Discussion: According to our estimation methods, the complete cost of adjuvant chemotherapy including trastuzumab will range from 1.3 to 2.4% of the global budget of the Moroccan Health Department (MAD 9.8 billion or USD 1.274 billion). Unfortunately, only one-third of the Moroccan population has healthcare insurance whereas for each patient the treatment with chemotherapy alone costs 1.15 times the annual minimum income (MAD 23,710 or USD 3,082), and treatment requiring both chemotherapy and trastuzumab costs 9.76 times the annual minimum income. For the tumour over expressing HER2Neu, we need to treat 25 women in order to save (cure) one woman: the calculated cost for one life saved is USD 663,000. The question is, is it cost-effective for an emerging country? [ABSTRACT FROM AUTHOR]

Published
2010
Full Text
View/download PDF

27. Fish Consumption Impact on Coronary Heart Disease Mortality in Morocco: A Mathematical Model with Optimal Control.

Author

Lamlili, E. N. Mohamed, Boutayeb, Abdesslam, Derouich, Mohamed, Boutayeb, Wiam, and Moussi, Abderrahmane

Subjects
*FISH as food, *FOOD consumption, *CORONARY disease, *MATHEMATICAL models, *OPTIMAL control theory, *COOKING
Abstract

Extending the results of a previous paper on the relationship between fish consumption and coronary heart disease, an optimal control approach is proposed in the present paper. The Pontryagin's minimum principle is used to characterize the optimal control, to minimize the population of susceptible individuals and also to reduce the mortality rate of coronary heart disease. A numerical simulation is carried out to show the impact of the proposed optimal control. Indeed, the model shows that the prevalence and mortality of coronary heart disease can be significantly reduced in a period of 10 years. [ABSTRACT FROM AUTHOR]

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results